Why the study?
Data regarding the use of mavacamten in patients with mid-cavitary obstruction (MCO) are limited.
Does mavacamten reduce obstruction and improve symptoms in a patient with symptomatic mid-cavitary obstruction hypertrophic cardiomyopathy?
Does mavacamten reduce obstruction and improve symptoms in a patient with symptomatic mid-cavitary obstruction hypertrophic cardiomyopathy?
Mavacamten may effectively reduce obstruction and improve symptoms in patients with mid-cavitary obstruction hypertrophic cardiomyopathy, expanding its potential utility beyond standard left ventricular outflow tract obstruction.
May support mavacamten in mid-cavitary HCM; leaves open confirmation beyond this case report.
BACKGROUND: Mavacamten, a small molecule that inhibits cardiac myosin, has shown promise in reducing symptoms and improving cardiac function in patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction. However, data regarding the use of mavacamten in patients with mid-cavitary obstruction (MCO) are limited. CASE SUMMARY: This case report describes the therapeutic success in managing a 56-year-old man presenting with symptomatic MCO, a variant of HCM, through the combined administration of metoprolol and mavacamten. DISCUSSION: Despite the primary evidence for the efficacy of mavacamten being derived from patients with LVOT obstruction, this case demonstrates significant symptomatic improvement and reduced obstruction after treatment with mavacamten. TAKE-HOME MESSAGE: Mavacamten may be effective beyond its primary indication for LVOT obstruction in HCM, highlighting a potential new avenue for the treatment of MCO.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: